Europe Surgical Site Infection Control Market Forecast 2024-2032

The Europe surgical site infection control market is evaluated to progress with a CAGR of 4.44% during the forecast period of 2024-2032. The rising prevalence of surgical site infections (SSIs) is a significant factor driving the growth of the surgical site infection control market in Europe.

MARKET INSIGHTS

Additionally, increasing research and development activities are anticipated to further support market expansion as advancements in infection prevention techniques and technologies continue to emerge. Key preventive measures, such as general hygiene, hand hygiene practices, appropriate hair removal, antibiotic prophylaxis, and maintaining normothermia, are critical in reducing the incidence of SSIs. These measures contribute directly to the growth of the SSI control market in Europe by enhancing infection prevention protocols and improving patient outcomes.

REGIONAL ANALYSIS

The Europe surgical site infection control market growth assessment comprises a detailed evaluation of the United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe. According to Public Health England (PHE), surgical site infections (SSIs) accounted for approximately 16% of all healthcare-associated infections (HAIs) in England, making them the third most common type of HAI in the country. The PHE report highlighted an increasing trend in SSIs, particularly among patients undergoing knee prosthesis, large bowel, and cholecystectomy surgeries. The report also identified that nearly half of the pathogens causing SSIs were Enterobacteriaceae and meticillin-sensitive Staphylococcus aureus (MSSA).

Further, the financial burden associated with SSIs is substantial, with costs ranging from GBP 2,100 to GBP 10,500 per infection, depending on the complexity of the surgery, and escalating to as much as GBP 20,000 for complex surgeries. To address this issue, the UK government has implemented various preventive measures, including the Surgical Site Infection Surveillance Service managed by England's Healthcare-Associated Infection and Antimicrobial Resistance Department (HCAI & AMR). This service provides hospitals with protocols and analytical tools to monitor SSIs while accounting for key risk factors. As a result, government efforts in preventing SSIs are expected to stabilize and promote the growth of the SSI control market in the United Kingdom.

In France, SSIs are among the most frequent hospital-acquired infections in surgical patients, contributing significantly to mortality, morbidity, and healthcare costs. According to the European Centre for Disease Prevention and Control, the overall incidence rate of SSIs in France is 20% of all surgical procedures. Common surgeries associated with SSIs include coronary artery bypass grafts, cholecystectomies, colon surgeries, cesarean sections, and hip and knee prostheses, among others.

France has implemented a national SSI surveillance solution, the RAISIN surveillance system, which has been operational since 1999. This system is structured on a pyramidal organization at local, regional, and national levels and follows standard guidelines established in 1992 by the American Centers for Disease Control and Prevention (CDC)'s National Nosocomial Infections Surveillance (NNIS) system. Hence, the increasing incidence of SSIs in France remains a key driver of growth in the country's SSI control market, with an incidence rate of approximately one SSI per 100 procedures.

SEGMENTATION ANALYSIS

The Europe surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The procedure segment is further classified into laparoscopy, orthopedic surgery, cardiovascular, obstetrics and gynecology, wound closure, plastic & reconstructive surgery, thoracic surgery, microvascular, urology, neurosurgery, and other procedures.

Cardiovascular surgery involves heart-related procedures performed to address complications arising from ischemic heart disease, valvular heart disease, and congenital heart defects, including heart transplant surgeries. Given the high prevalence of cardiac diseases globally, the demand for cardiovascular surgical equipment is substantial. Instruments used in these surgeries include clamps, cutting devices, needle holders, retractors, scalpels, vascular dilators, forceps, powered instruments such as sternal saws and sternotomes, internal defibrillator paddles, and specialized valve surgery instruments like hooks, suture holding frames, and valve dilators.

Similarly, obstetrics and gynecology surgeries represent a significant revenue stream for surgical equipment manufacturers due to their large-scale performance. These procedures require a diverse range of instruments, including scalpels, speculums, forceps, cannulas, Metzenbaum scissors, curettes, laparoscopic instruments, Veress needles, trochars, catheters, and colposcopes. Market growth in this segment is driven by factors such as the changing lifestyle of women, the prevalence of various gynecological conditions, a growing demand for minimally invasive surgical alternatives to hysterectomy, advancements in gynecological procedures, high healthcare expenditure, and an aging population.

COMPETITIVE INSIGHTS

Leading players operating in the Europe surgical site infection control market include Belimed AG, bioMerieux SA, GAMA Healthcare, Getinge AB, etc.

Belimed AG is a leading global supplier of cleaning, disinfecting, and sterilizing products for the medical and life sciences industries. The company maintains an extensive network of sales subsidiaries and authorized partners, spanning over 80 countries worldwide. Belimed serves a broad customer base, including multinational pharmaceutical manufacturers, local hospitals, and large medical practices.

The company also delivers comprehensive products and solutions that go beyond equipment supply, offering additional services such as planning, simulation, validation, and ongoing support. Headquartered in Switzerland, the company has a strong presence across Europe, North America, and China.

Product Code: 96044

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
- 2.5.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET
- 2.5.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. SURGE IN GERIATRIC POPULATION
- 3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
- 3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
3.2. KEY RESTRAINTS
- 3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
- 3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS
- 3.2.3. RISING USE OF OUTPATIENT TREATMENTS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. RISING RATE OF SURGICAL PROCEDURES
- 4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
- 4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS
4.2. PORTER'S FIVE FORCES ANALYSIS
- 4.2.1. BUYERS POWER
- 4.2.2. SUPPLIERS POWER
- 4.2.3. SUBSTITUTIONS
- 4.2.4. NEW ENTRANTS
- 4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING FOR GERMANY
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS

5. MARKET BY PROCEDURE

5.1. LAPAROSCOPY
5.2. ORTHOPEDIC SURGERY
5.3. CARDIOVASCULAR
5.4. OBSTETRICS AND GYNECOLOGY
5.5. WOUND CLOSURE
5.6. PLASTIC & RECONSTRUCTIVE SURGERY
5.7. THORACIC SURGERY
5.8. MICROVASCULAR
5.9. UROLOGY
5.10. NEUROSURGERY
5.11. OTHER PROCEDURES

6. MARKET BY TYPE OF INFECTION

6.1. SUPERFICIAL INCISIONAL SSI
6.2. DEEP INCISIONAL SSI
6.3. ORGAN OR SPACE SSI

7. MARKET BY END-USER

7.1. HOSPITALS
7.2. AMBULATORY SURGICAL CENTERS

8. MARKET BY PRODUCT

8.1. DISINFECTANTS
- 8.1.1. SKIN DISINFECTANTS
- 8.1.2. HAND DISINFECTANTS
8.2. MANUAL REPROCESSORS SOLUTIONS
8.3. SURGICAL DRAPES
8.4. SURGICAL GLOVES
8.5. SKIN PREPARATION SOLUTIONS
8.6. SURGICAL IRRIGATION
8.7. SURGICAL SCRUBS
8.8. HAIR CLIPPERS
8.9. MEDICAL NONWOVENS
8.10. OTHER PRODUCTS

9. GEOGRAPHICAL ANALYSIS

9.1. EUROPE
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. EUROPE SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
- 9.1.3. EUROPE SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
- 9.1.4. KEY PLAYERS IN EUROPE SURGICAL SITE INFECTION CONTROL MARKET
- 9.1.5. COUNTRY ANALYSIS
  - 9.1.5.1. UNITED KINGDOM
  - 9.1.5.1.1. UNITED KINGDOM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.2. GERMANY
  - 9.1.5.2.1. GERMANY SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.3. FRANCE
  - 9.1.5.3.1. FRANCE SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.4. ITALY
  - 9.1.5.4.1. ITALY SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.5. SPAIN
  - 9.1.5.5.1. SPAIN SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.6. POLAND
  - 9.1.5.6.1. POLAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.7. BELGIUM
  - 9.1.5.7.1. BELGIUM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
  - 9.1.5.8. REST OF EUROPE
  - 9.1.5.8.1. REST OF EUROPE SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES

10. COMPETITIVE LANDSCAPE

10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PARTNERSHIPS & AGREEMENTS
- 10.1.3. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
- 10.2.1. 3M COMPANY
  - 10.2.1.1. COMPANY OVERVIEW
  - 10.2.1.2. PRODUCTS
  - 10.2.1.3. STRENGTHS & CHALLENGES
- 10.2.2. AMERICAN POLYFILM
  - 10.2.2.1. COMPANY OVERVIEW
  - 10.2.2.2. PRODUCTS
  - 10.2.2.3. STRENGTHS & CHALLENGES
- 10.2.3. ANSELL LTD
  - 10.2.3.1. COMPANY OVERVIEW
  - 10.2.3.2. PRODUCTS
  - 10.2.3.3. STRENGTHS & CHALLENGES
- 10.2.4. BECTON, DICKINSON AND COMPANY (BD)
  - 10.2.4.1. COMPANY OVERVIEW
  - 10.2.4.2. PRODUCTS
  - 10.2.4.3. STRENGTHS & CHALLENGES
- 10.2.5. BELIMED AG
  - 10.2.5.1. COMPANY OVERVIEW
  - 10.2.5.2. PRODUCTS
  - 10.2.5.3. STRENGTHS & CHALLENGES
- 10.2.6. BIOMERIEUX SA
  - 10.2.6.1. COMPANY OVERVIEW
  - 10.2.6.2. PRODUCTS
  - 10.2.6.3. STRENGTHS & CHALLENGES
- 10.2.7. GAMA HEALTHCARE
  - 10.2.7.1. COMPANY OVERVIEW
  - 10.2.7.2. PRODUCTS
  - 10.2.7.3. STRENGTHS & CHALLENGES
- 10.2.8. GETINGE AB
  - 10.2.8.1. COMPANY OVERVIEW
  - 10.2.8.2. PRODUCTS
  - 10.2.8.3. STRENGTHS & CHALLENGES
- 10.2.9. JOHNSON & JOHNSON
  - 10.2.9.1. COMPANY OVERVIEW
  - 10.2.9.2. PRODUCTS
  - 10.2.9.3. STRENGTHS & CHALLENGES
- 10.2.10. KIMBERLY-CLARK
  - 10.2.10.1. COMPANY OVERVIEW
  - 10.2.10.2. PRODUCTS
  - 10.2.10.3. STRENGTHS & CHALLENGES
- 10.2.11. SOTERA HEALTH LLC
  - 10.2.11.1. COMPANY OVERVIEW
  - 10.2.11.2. PRODUCTS
  - 10.2.11.3. STRENGTHS & CHALLENGES
- 10.2.12. STERIS CORPORATION
  - 10.2.12.1. COMPANY OVERVIEW
  - 10.2.12.2. PRODUCTS
  - 10.2.12.3. STRENGTHS & CHALLENGES
- 10.2.13. STRYKER CORPORATION
  - 10.2.13.1. COMPANY OVERVIEW
  - 10.2.13.2. PRODUCTS
  - 10.2.13.3. STRENGTHS & CHALLENGES

Product Code: 96044

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - SURGICAL SITE INFECTION CONTROL
TABLE 2: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY END-USER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY END-USER, FORECAST YEARS, 2024-2032 (IN $
TABLE 8: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 10: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 12: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 13: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 14: KEY PLAYERS OPERATING IN EUROPE SURGICAL SITE INFECTION CONTROL MARKET
TABLE 15: LIST OF MERGERS & ACQUISITIONS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR GERMANY
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, GROWTH POTENTIAL, BY PROCEDURE, IN 2023
FIGURE 7: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY LAPAROSCOPY, 2024-2032 (IN $ MILLION)
FIGURE 8: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY ORTHOPEDIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 9: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY CARDIOVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 10: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY OBSTETRICS AND GYNECOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 11: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY WOUND CLOSURE, 2024-2032 (IN $ MILLION)
FIGURE 12: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY PLASTIC & RECONSTRUCTIVE SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 13: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY THORACIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 14: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY MICROVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 15: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 16: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY NEUROSURGERY, 2024-2032 (IN $ MILLION)
FIGURE 17: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PROCEDURES, 2024-2032 (IN $ MILLION)
FIGURE 18: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, GROWTH POTENTIAL, BY TYPE OF INFECTION, IN 2023
FIGURE 19: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SUPERFICIAL INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 20: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DEEP INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 21: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY ORGAN OR SPACE SSI, 2024-2032 (IN $ MILLION)
FIGURE 22: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, GROWTH POTENTIAL, BY END-USER, IN 2023
FIGURE 23: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE 24: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY AMBULATORY SURGICAL CENTERS, 2024-2032 (IN $ MILLION)
FIGURE 25: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2023
FIGURE 26: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 27: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, GROWTH POTENTIAL, BY DISINFECTANTS, IN 2023
FIGURE 28: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 29: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY HAND DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 30: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY MANUAL REPROCESSORS SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 31: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL DRAPES, 2024-2032 (IN $ MILLION)
FIGURE 32: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL GLOVES, 2024-2032 (IN $ MILLION)
FIGURE 33: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN PREPARATION SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 34: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL IRRIGATION, 2024-2032 (IN $ MILLION)
FIGURE 35: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL SCRUBS, 2024-2032 (IN $ MILLION)
FIGURE 36: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY HAIR CLIPPERS, 2024-2032 (IN $ MILLION)
FIGURE 37: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY MEDICAL NONWOVENS, 2024-2032 (IN $ MILLION)
FIGURE 38: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 39: EUROPE SURGICAL SITE INFECTION CONTROL MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 40: UNITED KINGDOM SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 41: GERMANY SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 42: FRANCE SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 43: ITALY SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 44: SPAIN SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 45: POLAND SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 46: BELGIUM SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)
FIGURE 47: REST OF EUROPE SURGICAL SITE INFECTION CONTROL MARKET, 2024-2032 (IN $ MILLION)